August 24, 2022 admin

Daxor Corporation to Report First Half 2022 Financial Results on Thursday, August 25, 2022 & Provide Corporate Update

Conference Call to be held on the same day at 4:30 p.m. Eastern Time

Oak Ridge, TN – August 24, 2022 Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, will report financial results for the six months ending June 30, 2022 on Thursday, August 25, 2022 at approximately 4:00 p.m. Eastern Time.

President and CEO Michael Feldschuh and CFO Robert Michel will also host an earnings conference call at 4:30 p.m. ET on Thursday, August 25, 2022 to review financial results and provide an update on corporate developments.  Following management’s formal remarks, there will be a question-and- answer session.  Investors are invited to submit questions in advance to the following email address:

To listen to the conference call, interested parties within the U.S. should dial 1-877-317-6789. International callers may dial in at 1-412-317-6789.  All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Daxor Corporation conference call.  

The conference call will also be available through a live webcast that can be accessed at:

The webcast replay will be available until November 25, 2022 and can be accessed through the above link or on the Company’s website at

About Daxor Corporation

Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation.  We developed and market the BVA-100™ (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms.  Over 60,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care.  Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense.  Daxor’s mission is to advance healthcare by enabling optimal fluid management with blood volume analysis.  Daxor’s vision is optimal blood volume for all.  For more information, please visit our website at

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels.  Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties.  Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC.  Forward-looking statements speak only as of the date when made.  Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:

Bret Shapiro
Sr. Managing Partner, CORE IR